RAPT Therapeutics Future Growth
Future criteria checks 0/6
RAPT Therapeutics's earnings are forecast to decline at 5.5% per annum while its annual revenue is expected to grow at 62.4% per year. EPS is expected to decline by 1% per annum. Return on equity is forecast to be -70.3% in 3 years.
Key information
-5.5%
Earnings growth rate
-1.0%
EPS growth rate
Biotechs earnings growth | 30.3% |
Revenue growth rate | 62.4% |
Future return on equity | -70.3% |
Analyst coverage | Good |
Last updated | 31 May 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 16 | -235 | -209 | -178 | 3 |
12/31/2025 | N/A | -132 | -152 | -132 | 9 |
12/31/2024 | N/A | -112 | -84 | -72 | 10 |
3/31/2024 | N/A | -118 | -106 | -106 | N/A |
12/31/2023 | N/A | -117 | -98 | -97 | N/A |
9/30/2023 | N/A | -109 | -93 | -92 | N/A |
6/30/2023 | N/A | -99 | -89 | -87 | N/A |
3/31/2023 | 1 | -93 | -75 | -74 | N/A |
12/31/2022 | 2 | -84 | -72 | -71 | N/A |
9/30/2022 | 2 | -79 | -70 | -69 | N/A |
6/30/2022 | 3 | -76 | -65 | -64 | N/A |
3/31/2022 | 3 | -73 | -63 | -63 | N/A |
12/31/2021 | 4 | -69 | -62 | -61 | N/A |
9/30/2021 | 4 | -64 | -56 | -56 | N/A |
6/30/2021 | 5 | -60 | -54 | -53 | N/A |
3/31/2021 | 5 | -56 | -46 | -46 | N/A |
12/31/2020 | 5 | -53 | -41 | -40 | N/A |
9/30/2020 | 4 | -53 | -31 | -31 | N/A |
6/30/2020 | 2 | -49 | -33 | -33 | N/A |
3/31/2020 | 1 | -47 | -36 | -36 | N/A |
12/31/2019 | N/A | -43 | -36 | -35 | N/A |
9/30/2019 | N/A | -39 | -42 | -39 | N/A |
6/30/2019 | N/A | -40 | -39 | -36 | N/A |
3/31/2019 | N/A | -37 | -37 | -34 | N/A |
12/31/2018 | N/A | -36 | -36 | -33 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0RA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 0RA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 0RA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 0RA is forecast to have no revenue next year.
High Growth Revenue: 0RA is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 0RA is forecast to be unprofitable in 3 years.